News
Mounting concerns that FDA reviewers could start missing PDUFA deadlines have put many on edge. The moment calls for ...
After the gutting of the Department of Health and Human Services, fears mount about the future direction of the FDA—with ...
Vanda Pharmaceuticals is suing the FDA again, this time alleging the agency is unlawfully delaying a hearing to discuss the ...
2d
Pharmaceutical Technology on MSNFDA layoffs and priority review voucher programme’s lapse disrupt rare disease pipelineThe expiration of the FDA’s paediatric priority review voucher programme is creating uncertainty for rare disease drug ...
Two former FDA leaders look at Commissioner Marty Makary’s early stumbles — and lay out a list of priorities to protect both ...
On a recent call with analysts at BMO Capital Markets, a “former director” at the FDA’s Center for Biologics Evaluation and ...
After mass layoffs, the FDA has started missing certain deadlines, pushing one biopharma to delay a phase 3 trial and ...
They cited concerns about a possible link between consumption of the dyes and health conditions like ADHD, obesity and ...
In recent weeks, biotech companies have faced setbacks in moving forward with clinical trials due to operational delays at the FDA, according ... jeopardize potential product launches — issues ...
The Trump administration’s recent announcement that it plans to eliminate about 3,500 FDA jobs is creating uncertainty among ...
U.S. Food and Drug Administration Commissioner Martin Makary announced on Thursday a policy to limit employees of companies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results